Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 3/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 2/20 | 0.34 |
| ▸ | CELA1 | Q9UNI1 | 1/20 | 0.34 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16902988 | 0.89 | HTT (0.49) | KDM4EHTTHSD17B10GAATP53 | |
| SCHEMBL10790928 | 0.83 | HTT (0.49) | KDM4EHTTHSD17B10GAATP53 | |
| SCHEMBL8675250 | 0.83 | KDM4E (0.49) | KDM4EHTTHSD17B10GAATP53 | |
| SCHEMBL349293 | 0.82 | KDM4E (0.50) | KDM4EHTTHSD17B10GAATP53 | |
| SCHEMBL11338567 | 0.80 | HTT (0.50) | KDM4EHTTHSD17B10GAATP53 | |
| SCHEMBL8830632 | 0.80 | TOP1 (0.57) | KDM4EHTTHSD17B10GAAMAPT | |
| SCHEMBL31582335 | 0.80 | ABCB11 (0.41) | KDM4EHTTHSD17B10GAATP53 | |
| SCHEMBL22991582 | 0.80 | KDM4E (0.46) | KDM4EHTTHSD17B10GAATP53 | |
| SCHEMBL986584 | 0.79 | ALDH1A1 (0.46) | KDM4EGAAALDH1A1HPGDTUBB4A | |
| SCHEMBL3156904 | 0.79 | KDM4E (0.52) | KDM4EHTTHSD17B10GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2020-11-12 | — | — | US | disclosed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | disclosed |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2016-04-21 | — | — | US | disclosed |
| US-9199990-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2015-12-01 | — | — | US | disclosed |
| EP-2660238-B1 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP (CA) | 2015-05-06 | — | — | EP | disclosed |
| EP-2660238-B1 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP (CA) | 2015-05-06 | — | — | EP | disclosed |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (US) | 2015-03-12 | — | — | US | disclosed |
| US-8952021-B2 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-8952021-B2 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2015-02-10 | — | — | US | disclosed |
| EP-2382194-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2011-11-02 | — | — | EP | disclosed |
| EP-2314295-A1 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | Resverlogix, Inc (CA) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010079431-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010079431-A2 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2010-07-15 | — | — | WO | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| EP-1909788-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007016525-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES | RESVERLOGIX CORP. (CA) | 2007-02-08 | — | — | WO | disclosed |
| US-6087502-A | COMPOUNDS FOR MARKING ANTIGENS OR ANTIBODIES RECEPTOR BINDING ASSAY | MOCHIDA PHARMACEUTICALS CO., LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| EP-0761652-A1 | Acridinium compound having a plurality of luminescent groups and binding groups, and conjugate thereof | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | KDM4E 4404/4885HTT 1248/4885HSD17B10 254/4885 |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | KDM4E 4404/4885HTT 1248/4885HSD17B10 254/4885 |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | KDM4E 2334/4885HTT 1722/4885HSD17B10 2222/4885 |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | KDM4E 4404/4885HTT 1248/4885HSD17B10 254/4885 |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | KDM4E 4404/4885HTT 1248/4885HSD17B10 254/4885 |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | KDM4E 4404/4885HTT 1248/4885HSD17B10 254/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | KDM4E 2993/4885HTT 1309/4885HSD17B10 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.